Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunic ( (IMUX) ) has issued an announcement.
On February 12-13, 2026, Immunic, Inc. announced an oversubscribed private placement of pre-funded warrants and common stock warrants that will deliver $200 million in upfront gross proceeds, with the potential for an additional $200 million if the warrants are exercised. The financing, led by BVF Partners and joined by a roster of prominent healthcare investors, is expected to fund completion of phase 3 ENSURE trials in relapsing multiple sclerosis, initiation of a phase 3 program in primary progressive multiple sclerosis, and operating needs into late 2027.
As part of the same financing package, Immunic agreed a royalty purchase arrangement in which holders will exchange 51,087,000 Series B warrants issued in June 2025 for a pro rata share of a 5% synthetic royalty on future sales of vidofludimus calcium, reducing outstanding warrants and aligning investors with future product revenues. Governance is also being reshaped, with Roche veteran Simona Skerjanec elevated to interim chairperson, BVF’s Thor Nagel joining the board, and a search underway for a new CEO with multiple sclerosis commercial experience, underscoring Immunic’s planned transition into a commercial-stage MS player.
The most recent analyst rating on (IMUX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
The score is weighed down primarily by weak financial performance (no revenue, large losses, and significant cash burn with worsening free cash flow) and a negative corporate event tied to Nasdaq bid-price compliance. Technicals provide only modest near-term support, while valuation offers limited support due to ongoing losses and no dividend.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic and gastrointestinal diseases, with a near-term commercial emphasis on multiple sclerosis. Its lead asset, vidofludimus calcium, targets both relapsing and progressive forms of multiple sclerosis via a first-in-class dual mechanism combining Nurr1 activation and selective DHODH inhibition.
The company is positioning itself to evolve from an R&D-driven organization into a fully integrated commercial entity, building medical and commercial infrastructure around the potential launch of vidofludimus calcium in relapsing multiple sclerosis and the advancement of a phase 3 program in primary progressive multiple sclerosis. Board refreshment and leadership changes are aimed at bolstering commercial expertise as Immunic approaches late-stage data and possible regulatory milestones.
Average Trading Volume: 1,570,589
Technical Sentiment Signal: Sell
Current Market Cap: $89.29M
See more data about IMUX stock on TipRanks’ Stock Analysis page.